Application and Agreement for Lonafarnib

PRF Lonafarnib Application and Agreement June 2024 Page 1 of 5 Application and Agreement for Lonafarnib The Progeria Research Foundation Lonafarnib Pre-clinical Drug Supply Program For Progeria General Information: It is essential for the research community to continue investigating the effects of lonafarnib on HGPS through preclinical studies. Lonafarnib has shown some benefit [...] It is very important that donors understand both the importance and the usefulness of their donations. INSTRUCTIONS: a: Layman’s Statement for The Progeria Research Foundation. [...] (This may be used for press announcements, the PRF newsletter and on PRF’s web site.) b: Provide a short scientific description of the research you will conduct using the Compound. [...] PRF Lonafarnib Application and Agreement June 2024 Page 3 of 5 This application is reviewed for relevance to progeria research by PRF’s Medical Director. [...] Please note that a new PRF application is required for each future research project in which you plan to use the Compound for a purpose different from what you describe in this application and from what is in the executed MTA. [...] PRF Lonafarnib Application and Agreement June 2024 Page 4 of 5 The Progeria Research Foundation Lonafarnib Drug Supply Program Agreement Application forms must be completed as set forth, with supporting documentation attached. [...] As set forth in the MTA, the Compound will be supplied "As Is." For example, Certificate of Analysis may be included with each shipment and may indicate that the retest date is past-due. [...] The Progeria Research Foundation is not responsible for any loss, damage or mishandling once the Compound leaves its possession. [...] PRF requires that the Compound from the Lonafarnib Drug Supply Program is distributed solely for use in your laboratory and is non-transferable to other parties. PRF does not want to prevent scientific collaboration but wishes all those wanting to use this Compound to be applicants for use. PRF wants to avoid any and all conflicts of interest or undisclosed use of this Compound. [...] It is a goal of PRF to be aware of the scientific progress being made that could potentially lead to human clinical trials for progeria.